<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148343</url>
  </required_header>
  <id_info>
    <org_study_id>IRB04-00104</org_study_id>
    <secondary_id>R01HD044816</secondary_id>
    <nct_id>NCT00148343</nct_id>
  </id_info>
  <brief_title>Functional Electrical Stimulation for Footdrop in Hemiparesis</brief_title>
  <official_title>Functional Electrical Stimulation for Footdrop in Hemiparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to determine if electrical stimulation can improve the
      strength and coordination of the lower limb muscles, and the walking ability of stroke
      survivors.

      The knowledge gained from this study may lead to enhancements in the quality of life of
      stroke survivors by improving their neurological recovery and mobility. The results may lead
      to substantial changes in the standard of care for the treatment of lower limb hemiparesis
      after stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemiplegia is a major consequence of stroke and contributes significantly to the physical
      disability of stroke survivors. Foot-drop, or inability to dorsiflex the paretic ankle during
      the swing phase of gait, and ankle instability during stance phase, are important gait
      abnormalities that contribute to reduced mobility among stroke survivors. In the United
      States, the standard of care in addressing these deficits is the custom molded
      ankle-foot-orthosis (AFO). However, evolving data now demonstrate that active repetitive
      movement training is the principal substrate for facilitating motor relearning after stroke.
      Motor relearning is defined as the reacquisition of motor ability after central nervous
      system injury. Thus, while an AFO may assist stroke survivors to ambulate in the short-term,
      it is possible that it also inhibits recovery in the long-term. Previous studies have
      demonstrated that active repetitive movement exercises mediated by neuromuscular electrical
      stimulation (NMES) facilitate motor relearning among stroke survivors. In particular, studies
      have reported that some chronic stroke survivors treated with a peroneal nerve stimulator for
      foot-drop experience sufficient recovery that they no longer need the peroneal nerve
      stimulator or an AFO for community ambulation. However, there are no blinded randomized
      clinical trials that rigorously evaluate the motor relearning effects of ambulation training
      with peroneal nerve stimulators. Thus, the primary aim of this project is to assess the
      effects of transcutaneous peroneal nerve stimulation on lower limb motor relearning among
      chronic stroke survivors. The secondary aim is to assess the effects of transcutaneous
      peroneal nerve stimulation on lower limb mobility (disability) and overall quality of life. A
      single-blinded randomized clinical trial will be carried out to assess the effects of
      ambulation training with a peroneal nerve stimulator among chronic stroke survivors compared
      to ambulation training with conventional standard of care (which may include an AFO).
      Subjects will be treated for 12 weeks and followed for a total of another 6 months. This
      project will determine the effectiveness of peroneal nerve stimulation in facilitating motor
      relearning and improving the mobility and quality of life of stroke survivors. This proposed
      approach is expected to improve patient outcome and challenge the present clinical paradigm
      of prescribing AFOs for stroke survivors with foot-drop.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2, 2010</completion_date>
  <primary_completion_date type="Actual">August 2, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Assessment (FMA)</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steps Per Minute</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>The number of steps taken by participants in one minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Emory Functional Ambulation Profile(mEFAP)</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the &quot;timed up-and-go&quot; test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke-Specific Quality of Life Scale (SS-QOL)</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales.
Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Speed</measure>
    <time_frame>baseline, 12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Stroke</condition>
  <condition>Hemiplegia</condition>
  <arm_group>
    <arm_group_label>ODFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Odstock Dropped-Foot Stimulator (ODFS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (inc. AFO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Odstock Dropped-Foot Stimulator (ODFS)</intervention_name>
    <description>Device implementation &amp; use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.</description>
    <arm_group_label>ODFS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Standard of Care</intervention_name>
    <description>Conventional standard of care (which may include implementation &amp; use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.</description>
    <arm_group_label>Standard of Care (inc. AFO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Traditional Physical Therapy Treatment</intervention_name>
    <description>Traditional physical therapy treatment for 12 weeks.</description>
    <arm_group_label>ODFS</arm_group_label>
    <arm_group_label>Standard of Care (inc. AFO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stroke survivors &gt;90 days from most recent clinical hemorrhagic or nonhemorrhagic
             stroke

          -  Age: 18-80 years

          -  Unilateral hemiparesis

          -  Medically stable

          -  Sufficient endurance &amp; motor ability to ambulate at least 30 feet continuously with
             minimal assistance [requiring contact guard to no more than 25% physical help] or less
             without the use of an AFO

          -  Berg Balance Scale score of 24 or greater without any assistive devices

          -  Ankle dorsiflexion strength of no greater than 4/5 on the Medical Research Council
             (MRC) scale while standing

          -  Demonstrate foot-drop during ambulation such that gait instability [need for
             supervision, physical assistance or assistive device (cane, walker) to maintain
             balance or prevent falls] or inefficient gait patterns [gait pattern manifesting
             &quot;dragging&quot; or &quot;catching&quot; of the affected toes during swing phase of gait, or use of
             compensatory strategies such as circumducting the affected limb, vaulting with the
             unaffected limb or hiking the affected hip to clear the toes] are exhibited

          -  Ankle dorsiflexion to at least neutral while standing in response to NMES of the
             common peroneal nerve without painful hypersensitivity to the NMES

          -  If using an AFO, willing to terminate its use and comply with study requirements

        Exclusion Criteria:

          -  Require an AFO to maintain knee stability (prevention of knee flexion collapse) during
             stance phase of gait

          -  Edema of the affected lower limb which interferes with the safe and effective use of a
             peroneal nerve stimulator

          -  Skin breakdown of the affected lower limb which interferes with the safe and effective
             use of a peroneal nerve stimulator

          -  Absent sensation of the affected lower limb

          -  History of potentially fatal cardiac arrhythmias, such as ventricular tachycardia,
             supraventricular tachycardia, and rapid ventricular response atrial fibrillation with
             hemodynamic instability

          -  Demand pacemakers or any other implanted electronic systems

          -  Pregnant women

          -  Uncontrolled seizure disorder

          -  Parkinson's Disease

          -  Spinal cord injury

          -  Traumatic brain injury with evidence of motor weakness

          -  Multiple sclerosis

          -  Fixed ankle plantar flexor contracture

          -  Peroneal nerve injury at the fibular head as the cause of foot-drop

          -  Uncompensated hemineglect

          -  Severely impaired cognition and communication

          -  Painful hypersensitivity to NMES of the common peroneal nerve

          -  Inadequate social support (potential unlikeliness to comply with treatment &amp;
             follow-up)

          -  History of Botulinum toxin (Botox) injection to either of the lower extremities within
             the 3 month period preceding study entry

          -  Knee hyperextension (genu recurvatum) that cannot be adequately corrected with
             peroneal nerve stimulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Chae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://fescenter.org/index.php</url>
    <description>Cleveland FES Center</description>
  </link>
  <reference>
    <citation>Burridge JH, Taylor PN, Hagan SA, Wood DE, Swain ID. The effects of common peroneal stimulation on the effort and speed of walking: a randomized controlled trial with chronic hemiplegic patients. Clin Rehabil. 1997 Aug;11(3):201-10.</citation>
    <PMID>9360032</PMID>
  </reference>
  <reference>
    <citation>Burridge J, Taylor P, Hagan S, Swain I. Experience of clinical use of the Odstock dropped foot stimulator. Artif Organs. 1997 Mar;21(3):254-60.</citation>
    <PMID>9148719</PMID>
  </reference>
  <reference>
    <citation>Burridge JH, McLellan DL. Relation between abnormal patterns of muscle activation and response to common peroneal nerve stimulation in hemiplegia. J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):353-61.</citation>
    <PMID>10945810</PMID>
  </reference>
  <reference>
    <citation>Burridge JH, Wood DE, Taylor PN, McLellan DL. Indices to describe different muscle activation patterns, identified during treadmill walking, in people with spastic drop-foot. Med Eng Phys. 2001 Jul;23(6):427-34.</citation>
    <PMID>11551819</PMID>
  </reference>
  <reference>
    <citation>Taylor PN, Burridge JH, Dunkerley AL, Wood DE, Norton JA, Singleton C, Swain ID. Clinical use of the Odstock dropped foot stimulator: its effect on the speed and effort of walking. Arch Phys Med Rehabil. 1999 Dec;80(12):1577-83.</citation>
    <PMID>10597809</PMID>
  </reference>
  <reference>
    <citation>Taylor PN, Burridge JH, Dunkerley AL, Lamb A, Wood DE, Norton JA, Swain ID. Patients' perceptions of the Odstock Dropped Foot Stimulator (ODFS). Clin Rehabil. 1999 Oct;13(5):439-46.</citation>
    <PMID>10498351</PMID>
  </reference>
  <reference>
    <citation>Taylor P, Burridge J. Functional Electrical Stimulation - the Odstock Dropped Foot Stimulator. In: Sassoon R, ed. Understanding Stroke: Pardoe Blacker Publishing Ltd, 2002:72-78.</citation>
  </reference>
  <reference>
    <citation>Taylor P. The use of electrical stimulation for correction of dropped foot in subjects with upper motor neuron lesions. Advances in Clinical Neurosciences and Rehabilitation 2002; 2:16-18.</citation>
  </reference>
  <reference>
    <citation>Chae J, Bethoux F, Bohine T, Dobos L, Davis T, Friedl A. Neuromuscular stimulation for upper extremity motor and functional recovery in acute hemiplegia. Stroke. 1998 May;29(5):975-9.</citation>
    <PMID>9596245</PMID>
  </reference>
  <reference>
    <citation>Francisco G, Chae J, Chawla H, Kirshblum S, Zorowitz R, Lewis G, Pang S. Electromyogram-triggered neuromuscular stimulation for improving the arm function of acute stroke survivors: a randomized pilot study. Arch Phys Med Rehabil. 1998 May;79(5):570-5.</citation>
    <PMID>9596400</PMID>
  </reference>
  <reference>
    <citation>Mann GE, Wright PA, Swain ID. Training effects of electrical stimulation and the conventional ankle foot orthosis in the correction of drop foot following stroke., 1st Annual Conference of FESnet, 2002.</citation>
  </reference>
  <reference>
    <citation>Taylor P, Mann G, Swain I. Does prior use of an Ankle Foot Orthosis (AFO) effect the response to use of the Odstock Dropped Foot Stimulator?, Institute of Physics and Engineering in Medicine (IPEM) Annual Scientific Meeting, Bath, U.K., September 15-17, 2003:89-90.</citation>
  </reference>
  <reference>
    <citation>Buurke JH, Roetenberg D, Kleissen RFM, Hermens HJ. Early recovery of gait after stroke, 3rd World Congress in Neurological Rehabilitation, Venice, Italy, April 2-6, 2002, 2002.</citation>
  </reference>
  <reference>
    <citation>El-Hayek K, Quinn A, Berezovskiy R, Santing J, Harley M, Chae J. Relationship between lower limb motor impairment and ambulation function among chronic stroke survivors. Submitted.</citation>
  </reference>
  <reference>
    <citation>Teasell RW, Bhogal SK, Foley NC, Speechley MR. Gait retraining post stroke. Top Stroke Rehabil. 2003 Summer;10(2):34-65.</citation>
    <PMID>13680517</PMID>
  </reference>
  <reference>
    <citation>Teasell RW, Foley NC, Bhogal SK, Speechley MR. An evidence-based review of stroke rehabilitation. Top Stroke Rehabil. 2003 Spring;10(1):29-58. Review.</citation>
    <PMID>12970830</PMID>
  </reference>
  <reference>
    <citation>International Society for Prosthetics and Orthotics. Consensus Conference on</citation>
  </reference>
  <reference>
    <citation>LIBERSON WT, HOLMQUEST HJ, SCOT D, DOW M. Functional electrotherapy: stimulation of the peroneal nerve synchronized with the swing phase of the gait of hemiplegic patients. Arch Phys Med Rehabil. 1961 Feb;42:101-5.</citation>
    <PMID>13761879</PMID>
  </reference>
  <reference>
    <citation>Waters RL, McNeal D, Perry J. Experimental correction of footdrop by electrical stimulation of the peroneal nerve. J Bone Joint Surg Am. 1975 Dec;57(8):1047-54.</citation>
    <PMID>1081538</PMID>
  </reference>
  <reference>
    <citation>Waters RL, McNeal DR, Clifford B. Correction of footdrop in stroke patients via surgically implanted peroneal nerve stimulator. Acta Orthop Belg. 1984 Mar-Apr;50(2):285-95.</citation>
    <PMID>6741512</PMID>
  </reference>
  <reference>
    <citation>Kljajić M, Malezic M, Aćimović R, Vavken E, Stanic U, Pangrsic B, Rozman J. Gait evaluation in hemiparetic patients using subcutaneous peroneal electrical stimulation. Scand J Rehabil Med. 1992 Sep;24(3):121-6.</citation>
    <PMID>1411357</PMID>
  </reference>
  <reference>
    <citation>van der Aa HE, Bultstra G, Verloop AJ, Kenney L, Holsheimer J, Nene A, Hermens HJ, Zilvold G, Buschman HP. Application of a dual channel peroneal nerve stimulator in a patient with a &quot;central&quot; drop foot. Acta Neurochir Suppl. 2002;79:105-7.</citation>
    <PMID>11974972</PMID>
  </reference>
  <reference>
    <citation>Merletti R, Andina A, Galante M, Furlan I. Clinical experience of electronic peroneal stimulators in 50 hemiparetic patients. Scand J Rehabil Med. 1979;11(3):111-21.</citation>
    <PMID>315098</PMID>
  </reference>
  <reference>
    <citation>Granat MH, Maxwell DJ, Ferguson AC, Lees KR, Barbenel JC. Peroneal stimulator; evaluation for the correction of spastic drop foot in hemiplegia. Arch Phys Med Rehabil. 1996 Jan;77(1):19-24.</citation>
    <PMID>8554468</PMID>
  </reference>
  <reference>
    <citation>Takebe K, Kukulka C, Narayan MG, Milner M, Basmajian JV. Peroneal nerve stimulator in rehabilitation of hemiplegic patients. Arch Phys Med Rehabil. 1975 Jun;56(6):237-9.</citation>
    <PMID>1079717</PMID>
  </reference>
  <reference>
    <citation>Takebe K, Basmajian JV. Gait analysis in stroke patients to assess treatments of foot-drop. Arch Phys Med Rehabil. 1976 Jul;57(1):305-10.</citation>
    <PMID>1084734</PMID>
  </reference>
  <reference>
    <citation>Stefancic M, Rebersek M, Merletti R. The therapeutic effects of the Ljublijana functional electrical brace. Eur Medicophys 1976; 12:1-9.</citation>
  </reference>
  <reference>
    <citation>Carnstam B, Larsson LE, Prevec TS. Improvement of gait following functional electrical stimulation. I. Investigations on changes in voluntary strength and proprioceptive reflexes. Scand J Rehabil Med. 1977;9(1):7-13.</citation>
    <PMID>302481</PMID>
  </reference>
  <reference>
    <citation>Sullivan SB. Stroke. In: Sullivan SB, ed. Physical Rehabilitation: Assessment and Treatment. Philadelphia: F. A. Davis Company, 1994:327-360.</citation>
  </reference>
  <reference>
    <citation>Verbeke G, Molenbergh G. Linear mixed models for longitudinal data. New York: Springer-Verlag, 2000.</citation>
  </reference>
  <reference>
    <citation>Harrell FE. Regression modeling strategies. New York: Springer-Verlag, 2001.</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>May 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2018</results_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>John Chae, MD</investigator_full_name>
    <investigator_title>Prof, Chair Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>hemiplegia</keyword>
  <keyword>hemiparesis</keyword>
  <keyword>stroke</keyword>
  <keyword>foot-drop</keyword>
  <keyword>electrical stimulation</keyword>
  <keyword>ankle-foot-orthosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemiplegia</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects screened over 5-yr study period: 469. Subjects completing informed consent and eligibility eval: 158. Subjects enrolled: 110. Last date of enrollment:10/27/2009. Final date subject study completion: 8/2/2010. All subject screening, enrollment, and study participation took place at an academic medical center.</recruitment_details>
      <pre_assignment_details>Enrolled subjects (n=110) were stratified by presence or absence of dorsiflexion, based on clinical exam, prior to randomization into treatment and control groups. No enrolled subjects were excluded from the trial prior to assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peroneal Nerve Stimulation (PNS)</title>
          <description>The peroneal nerve stimulator used in this study was the Odstock Dropped-Foot Stimulator (ODFS).</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care (no Device or Ankle Foot Orthosis)</title>
          <description>Conventional Standard of Care was defined as either 1) no device or 2) a custom molded hinged ankle foot orthosis (AFO). Standard of care intervention device was determined based on clinical indication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peroneal Nerve Stimulation</title>
          <description>Odstock Dropped Foot Stimulator</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>No device or ankle foot orthosis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="12.2"/>
                    <measurement group_id="B2" value="53.2" spread="10.1"/>
                    <measurement group_id="B3" value="53.0" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fugl-Meyer Motor Assessment (FMA)</title>
        <description>Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).</description>
        <time_frame>Weeks 0, 12, 24, 36</time_frame>
        <population>For intent-to-treat analysis, all participants who were randomized and completed baseline assessments were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Peroneal Nerve Stimulation</title>
            <description>Odstock Dropped Foot Stimulator</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>No device or ankle foot orthosis</description>
          </group>
        </group_list>
        <measure>
          <title>Fugl-Meyer Motor Assessment (FMA)</title>
          <description>Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).</description>
          <population>For intent-to-treat analysis, all participants who were randomized and completed baseline assessments were included in the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="5.9"/>
                    <measurement group_id="O2" value="20.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12- weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="6.27"/>
                    <measurement group_id="O2" value="21.18" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24- weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="6.05"/>
                    <measurement group_id="O2" value="21.17" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.93" spread="5.84"/>
                    <measurement group_id="O2" value="21.02" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>Mixed model analysis. Slope is in reference to treatment x time interaction for full 36 weeks</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steps Per Minute</title>
        <description>The number of steps taken by participants in one minute</description>
        <time_frame>Weeks 0, 12, 24, 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peroneal Nerve Stimulation</title>
            <description>Odstock Dropped Foot Stimulator</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>No device or ankle foot orthosis</description>
          </group>
        </group_list>
        <measure>
          <title>Steps Per Minute</title>
          <description>The number of steps taken by participants in one minute</description>
          <units>Steps/Min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="22"/>
                    <measurement group_id="O2" value="66.7" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="21.5"/>
                    <measurement group_id="O2" value="72.6" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="26.35"/>
                    <measurement group_id="O2" value="72.0" spread="23.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.84" spread="26.83"/>
                    <measurement group_id="O2" value="73.74" spread="22.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-5.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.05</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
            <estimate_desc>Slope is in reference to from baseline to end of follow-up at 36 weeks.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Emory Functional Ambulation Profile(mEFAP)</title>
        <description>The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the &quot;timed up-and-go&quot; test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.</description>
        <time_frame>Weeks 0, 12, 24, 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peroneal Nerve Stimulation</title>
            <description>Odstock Dropped Foot Stimulator</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>No device or ankle foot orthosis</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Emory Functional Ambulation Profile(mEFAP)</title>
          <description>The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the &quot;timed up-and-go&quot; test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.54" spread="86.59"/>
                    <measurement group_id="O2" value="118.39" spread="74.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12- weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.92" spread="78.80"/>
                    <measurement group_id="O2" value="93.47" spread="73.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.81" spread="81.89"/>
                    <measurement group_id="O2" value="97.25" spread="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.81" spread="83.16"/>
                    <measurement group_id="O2" value="96.20" spread="65.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.096</ci_lower_limit>
            <ci_upper_limit>14.716</ci_upper_limit>
            <estimate_desc>Slope is in reference to start of treatment to end of follow up at 36 weeks</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke-Specific Quality of Life Scale (SS-QOL)</title>
        <description>The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales.
Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.</description>
        <time_frame>Weeks 0, 12, 24, 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peroneal Nerve Stimulation</title>
            <description>Odstock Dropped Foot Stimulator</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>No device or ankle foot orthosis</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke-Specific Quality of Life Scale (SS-QOL)</title>
          <description>The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales.
Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.</description>
          <units>Summary Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.12" spread="35.73"/>
                    <measurement group_id="O2" value="175.30" spread="40.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.62" spread="42.39"/>
                    <measurement group_id="O2" value="185.42" spread="34.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.66" spread="38.25"/>
                    <measurement group_id="O2" value="184.87" spread="38.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.23" spread="44.73"/>
                    <measurement group_id="O2" value="182.95" spread="39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>-1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.79</ci_lower_limit>
            <ci_upper_limit>8.89</ci_upper_limit>
            <estimate_desc>Mixed models analysis. Slope refers to baseline to final follow up at 36 weeks</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gait Speed</title>
        <time_frame>baseline, 12, 24 and 36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peroneal Nerve Stimulation</title>
            <description>Odstock Dropped Foot Stimulator</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>No device or ankle foot orthosis</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Speed</title>
          <units>meters/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.20"/>
                    <measurement group_id="O2" value="0.40" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.25"/>
                    <measurement group_id="O2" value="0.47" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.28"/>
                    <measurement group_id="O2" value="0.46" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.28"/>
                    <measurement group_id="O2" value="0.47" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
            <estimate_desc>Slope is in reference to baseline to end of follow-up at 36 weeks</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peroneal Nerve Stimulation</title>
          <description>Odstock Dropped Foot Stimulator</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>No device or ankle foot orthosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic change</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="54"/>
                <counts group_id="E2" events="24" subjects_affected="15" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="54"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Uneven randomization with respect to dorsiflexion status and mEFAP at baseline.
High drop out rate of 30% for the ODFS and 20% for usual care
Optimal dose and duration of treatment unknown
Activity monitor on ODFS and AFO not reliable</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lynne Sheffler, MD</name_or_title>
      <organization>Case Western Reserve University/MetroHealth Medcial Center</organization>
      <phone>216-957-3570 ext 73556</phone>
      <email>lsheffler@metrohealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

